New research shows 92% of cancer patients stayed cancer-free for two years after immune-based therapy, potentially avoiding ...

According to the results of the early study, published simultaneously in the New England Journal of Medicine, 92% of patients ...

Adding pembrolizumab (Keytruda), before and after surgery, to standard adjuvant therapy for locally advanced head and neck ...

The new treatment, which uses a type of immune cell called natural killer cells, promoted complete remission in several ...

Neoadjuvant PD-1 blockade in dMMR tumors "could potentially eradicate the need for chemotherapy, radiation, and surgery in ...

Lyon, France-based late-stage clinical biotech MaaT Pharma has presented new preclinical data for MaaT034 at the American ...

Lyon, France-based late-stage clinical biotech MaaT Pharma has presented new preclinical data for MaaT034 at the American ...

The AACR meeting was full of promising data on the vaccine against cervical cancer, a lung cancer drug and the next ...

With the American Association for Cancer Research’s annual conference now underway, oncology researchers can expect ...

Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and ...

From a meeting that celebrates basic research and being "first," a look at 3 data sets on therapies that would break new ...